Plain-English translation of NCT07493317 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Major Depressive Disorder research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a medication called —which blocks a protein in your immune system—can help people with major depression, especially those who struggle to feel pleasure or enjoyment. Researchers believe that in some people with depression, the immune system may be overactive in ways that affect the brain's reward circuits. This study will give participants injections of over 8 weeks to see if it improves mood and the ability to experience joy.
Depression doesn't always respond well to traditional antidepressants, and many people continue to feel numb or unable to enjoy things even when their mood improves. This trial is exploring a completely new approach based on evidence suggesting that immune system activity may play a role in these persistent symptoms.
You likely qualify if…
You likely don't qualify if…
If you're accepted into the treatment group, you'll receive 5 injections of the medication under your skin over an 8-week period (one injection every 2 weeks). You'll also undergo brain imaging scans and blood tests at the beginning and end of the study to measure changes in how your brain's reward circuits function and to track immune markers. The entire study lasts about 8 weeks, plus follow-up visits to monitor your safety and progress.
AI-generated summary from trial data · Jul 17, 2026 · Not medical advice
United States